For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue from collaborations | - | 0* | - | - |
| Revenue from customers | 2,830 | 169* | 741 | 965 |
| Research and development | 23,352 | 17,038 | 23,937 | 13,976 |
| General and administrative | 6,407 | 4,945 | 5,165 | 5,556 |
| Total operating expenses | 29,759 | 21,983 | 29,102 | 19,532 |
| Loss from operations | -26,929 | -21,814 | -28,361 | -18,567 |
| Interest and other income, net | 811 | 750 | 1,085 | 1,207 |
| Change in fair value of 2023 common warrants | -3,395 | -1,213 | 4,205 | -1,682 |
| (loss) income before income tax | -22,723 | -19,851 | -31,481 | -15,678 |
| Income tax provision | 317 | 30 | 56 | 185 |
| Net (loss) income | -23,040 | -19,881 | -31,537 | -15,863 |
| Unrealized loss on available-for-sale securities | -30 | 18 | 35 | -27 |
| Unrealized loss on pension plans | - | 5 | - | - |
| Other comprehensive loss | -30 | 13 | 35 | -27 |
| Comprehensive (loss) income | -23,070 | -19,868 | -31,502 | -15,890 |
| Basic EPS | -2.21 | -1.908 | -3.04 | -1.53 |
| Diluted EPS | -2.21 | -1.965 | -3.04 | -1.53 |
| Basic Average Shares | 10,402,967 | 10,410,684 | 10,369,535 | 10,351,120 |
| Diluted Average Shares | 10,402,967 | 10,109,472 | 10,369,535 | 10,351,120 |
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)